-	
_	
\rightarrow	
\sim	

-4	
11	
1,7	
ļŲ	
. 4	
į.	
ŀ±	
4	
.=	

11-	14-	02
VI	/ /	Up

CERTIFICATE UNDER 37 C.F.R. 1.10

UTILITY	Express Mail Label No.:		
PATENT APPLICATION	Date of Deposit: Januar		

EL676470283US

Docket No.

IVD 978-2

ry 11, 2002

I hereby certify that this paper is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" Service on the date indicated above, and is addressed to: Commissioner, for Patents, Box Patent Application, Washington, DC 20231

(Only for new nonprovisional application under 37 CFR 1.53(b)) APPLICATION ELEMENTS

See MPEP chapter 600 concerning utility patent

application contents.

TRANSMITTAL

ADDRESS TO:

h.

Commissioner for Patents

Box Patent Application Washington, DC 20231

(Appendix)

(if applicable, all necessary)

X	Fee Transmittal Form

(Submit an original, and a duplicate for fee processing)

Specification

Total Pages (preferred arrangement set forth below)

- Descriptive Title of the Invention
- Cross References to Related Applications
- Statement Regarding Fed sponsored R & D
- Reference to Sequence Listing or a Table Appendix
- Background of the Invention
- Brief Summary of the Invention
- Brief Description of the Drawings (if filed)
- Detailed Description
- Claim(s)
- Abstract of the Disclosure

Drawing(s) (35 USC 113)

Total Sheets

X Oath or Declaration/ Power of Attorney

Total Sheets

- Newly executed (original or copy)
- Copy from a prior application (37 CFR 1.63(d)) (for continuation/divisional with Box 16 completed)

DELETION OF INVENTOR(S) Signed statement attached deleting inventor(s) named in the prior application, see 37 CFR 1.63(d)(2) and 1.33(b).

Application Data Sheet (See 37 CFR 1.76)

 ACCOMP	ANIVING	ADDI	ICATIO	NDADTE
ACCOMI	AUTHO	APPL	ICATIO	IN PARIS

Paper copy (identical to computer copy)

Statement verifying identity of above copies

CD-Rom or CD-R, Large Table or Computer Program

Nucleotide and/or Amino Acid Sequence Submission

Computer Readable Form (CFR)

- Assignment Papers (cover sheet & document(s))
- 37 CFR 3 73(b) Statement Power of Attorney
- English Translation Document (if applicable)
- 11. Information Disclosure Copies of IDS Statement (IDS)/PTO-1449 Citations
- 12. Preliminary Amendment
- Return Receipt Postcard (MPEP 503) (Should be specifically itemized)
- Request and Certification under 35 U.S.C. 122(b)(2)(B)(i)
- 15. X Other: Citation of References

16. If a CONTINUING APPLICATION, check appropriate box and supply the requisite information below and in a preliminary amendment or in an Application Data Sheet under 37 CFR 1.76:

Continuation Divisional

Continuation-in-part (CIP)

of prior application no:_

09/341,764

Prior Application Information:

Examiner: J. Kim

Group Art Unit:_

For CONTINUATION OR DIVISIONAL APPS only: The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 4b, is considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by reference. The incorporation can only be relied upon when a portion has been inadvertently omitted from the submitted application parts.

17. CORRESPONDENCE ADDRESS

Customer Number or Bar Code Label



Correspondence address

Michael D. Alexander Sanofi-Synthelabo Inc. 9 Great Valley Parkway Malvern, PA 19355 Telephone No.: (610) 889-8802

Facsimile No.: (610) 889-8799

lly submitted.

Michael D. Alexander Reg. No. 36,080

me January 11, 2002

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Division Under 37 C.F.R. 1.53(b) Application of: Maruani et al.

Prior Application Serial No.: 09/341,764

Prior Filing Date: August 19, 1999

Prior Group Art Unit: 1617

Anticipated Classification of this Application:

Class 514

Subclass 406.000

Examiner: J. Kim

For: USE OF CENTRAL CANNABINOID RECEPTOR ANTAGONISTS FOR THE

PREPARATION OF DRUGS

Commissioner for Patents Box Patent Application Washington, D.C. 20231

CERTIFICATE UNDER 37 C.F.R. 1.10

Express Mail Label Number: EL676470283US

Date of Deposit: January 11, 2002

I hereby certify that this paper is being deposited with the United States Postal Service "Express Mail Post Office to Addressee"Service on the date indicated above and is addressed to: Commissioner for Patents, Box Patent Application, Washington, DC 20231

Signature

FEE TRANSMITTAL FORM

The filing fee for the above-identified has been calculated as shown below:

		Claims	as Filed			
	Number	Number		Rate	Basic Fee	
	Filed		Extra			\$740.00
Total Claims	16	-20 =	0	X	\$ 18.00 =	
Independent Claims	2	- 3 =		X	\$ 84.00 =	
Multiple dependent claim	s(s), if any				\$280.00 =	
Total Filing Fee:						\$740.00

X Please charge the following fees to Deposit Account No. 19-0091.

X Filing Fee of \$740.00
Assignment recordal fee of \$

Please charge any additional fees under 37 CFR 1.16 which may be required, or credit any overpayment, to Deposit Account No. 19-0091. A duplicate copy of this sheet is enclosed.

This application is being filed by "Express Mail" as of the date of this letter pursuant to 37 CFR 1.10(b).

Date: January 11, 2003

Michael D. Alexander Reg. No. 36,080

Address:

Patent Department Sanofi-Synthelabo Inc. 9 Great Valley Parkway Malvern, PA 19355 Tele: (610) 889-8802 Fax: (610) 889-8799

Division	under	37	C.F.R.	1.53(b)
A 1* /				` ′

Application of:

MARUANI, Jeanne and SOUBIE, Philippe

Prior Application Serial No

09/341,764

Attorney Docket No.

IVD 978-2

Title:

USE OF CANNABINOID RECEPTOR

ANTAGONISTS FOR THE PREPARATION OF DRUGS

CERTIFICATE UNDER 37 C.F.R. 1.10

Express Mail Label No.:	EL676470283US
Date of Deposit:	January 11, 2002
Thomshire and Graffich 41	tto alora I Emplish Thomas to the control of

I hereby certify that the attached English Translation is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" Service on the date indicated above, and is addressed to:

Commissioner for Patents, Box PCT, <u>Attn</u>: EO/US, Washington, DC 20231

Signature